sapacitabine

Business news, market intelligence, and global industry analysis.

The Latest

Representative image showing an oil tanker under attack in the Strait of Hormuz as tensions involving Iran’s Islamic Revolutionary Guard Corps raise fears of a major supply disruption that analysts warn could push global oil prices toward $200 per barrel.

Iran: Get ready for $200 oil. IRGC fires on more ships in the Gulf

Haleon plc invests £65M in Shanghai oral health plant as China becomes central to its global growth strategy

Haleon (NYSE, LSE: HLN) bets on China’s oral health boom with £65m Shanghai manufacturing facility

Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?

Cargo theft is rising across North America. Can Eagle Vision Security’s iFM platform stop it before it starts?

Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial

Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not…

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

February 26, 2017